Recommendations for the Use of Disease‐Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review
Authors' conclusion
There is heterogeneity in the formulation of guidelines on the use of DMARDs in pregnancy. Recommendations for csDMARDs were similar between guidelines. There was significant variability in recommendations for bDMARD and tsDMARD use, reflecting current minimal literature in this area.
Study context
- Population
- Guidelines by academic rheumatology societies addressing disease-modifying antirheumatic drugs (DMARDs) in pregnancy in RA, AS, PsA and SLE
- Participants
- 18 guidelines
- Comparison
- Existing guideline recommendations for DMARD use in pregnancy and reproductive health
- Outcome
- Guideline coverage of DMARD recommendations
Methodological detailsMedline and Embase plus hand search, guidelines published since 2014, data extraction in duplicate
- Medline and Embase plus hand search
- Guidelines published since 2014
- Data extraction in duplicate
Main finding
As reported in the abstract
- Recommendations for DMARD use in preconception
- 10 guidelines (56%)
- Recommendations for lactation
- 12 guidelines (67%)
- Recommendations for male fertility
- 6 guidelines (33%)
- Recommendations for csDMARDs
- 13 guidelines (72%)
- Recommendations for bDMARDs
- 13 guidelines (72%)
- Recommendations for tsDMARDs
- 5 guidelines (28%)
Original publication
Recommendations for the Use of Disease‐Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review. Arthritis Care Res (Hoboken). Published 16 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →